Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEEP-G06A phase II study of sintilimab + fruquintinib + fecal microbiota transplantation in non-MSI-H/dMMR advanced colorectal cancer
ChiCTR2200056448Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and fruquintinib in colorectal cancer (CRC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective response rate. Started Jan 2022; status: recruiting.
02
Drugs
sintilimabfruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2200056448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056448.